Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Pharmaxis Announces 1st Patient Enrolled in Clinical Trial Studying a Potential New Treatment for Bone Marrow Cancer Myelogibrosis

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

February 22, 2021

Pharmaxis advises the phase 1c/2a trial cleared by the FDA under the Investigational New Drug (IND) scheme aims to demonstrate that PXS-5505, the lead asset in Pharmaxis’ drug discovery pipeline, is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs

Pharmaxis has completed site initiation at several Australian and South Korean hospitals and the first patient has been enrolled. The dose-escalation phase of the study that aims to select the optimum dose of PXS-5505.  This first phase, which will recruit up to 18 patients, is expected to conclude and report in 2H 2021 and will be followed by a six-month dose-expansion phase (24 patients) to evaluate safety and efficacy. Sites in other countries including the USA will be added for the dose-expansion phase.

PXS-5505 is an orally taken drug that inhibits the lysyl oxidase family of enzymes.  In pre-clinical models of myelofibrosis, PXS-5505 reversed the bone marrow fibrosis that drives morbidity and mortality in myelofibrosis and reduced many of the abnormalities associated with this disease.

Pharmaxis CEO Gary Phillips said, “PXS-5505 has demonstrated good tolerability and highly effective inhibition of the enzyme in phase 1 studies. Its potential to modify the course of the disease by directly targeting bone marrow fibrosis will make PXS-5505 an ideal monotherapy or adjunct to approved therapies in this indication. There remains a high level of unmet need in myelofibrosis and many other drugs in development have challenging side effect profiles.”

While Pharmaxis’s primary focus is the development of PXS-5505 for myelofibrosis, the drug also has potential in several other cancers including liver and pancreatic cancer where it aims to breakdown the fibrotic tissue in the tumor and enhance the effect of chemotherapy treatment. Learn more here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine